EMAIL THIS PAGE TO A FRIEND

Nanomedicine (London, England)

C-Type lectin receptor(s)-targeted nanoliposomes: an intelligent approach for effective cancer immunotherapy.


PMID 28756740

Abstract

The purpose of present approach is to target C-Type lectin (CTL) receptors for preferential uptake by the macrophages/dendritic cells and improving the cross-presentation of ovalbumin. Conventional and engineered nanoliposomes (MPNLs) were fabricated and extensively characterized. The nanoliposome(s) was spherical in shape; and their ζ potential, size and ovalbumin loading efficiency were recorded to be 268 ± 4.15 nm, 23.4 ± 0.35 mV, 46.65 ± 1.84%, respectively. The findings demonstrate that MPNLs significantly improved the antigen uptake and its cross-presentation to evoke Th CD8 In a nutshell, this engineered approach mannose surface modification for active targeting to dendritic cells/macrophages and pH-dependent quick endosomal antigen release is a promising system for efficient cancer immunotherapy.